May 5, 2020 / 11:51 PM / 25 days ago

BRIEF-CSL Says Unit To Begin Onshore Development Of Anti-SARS-CoV-2 Plasma Product

May 6 (Reuters) - CSL Ltd:

* UNIT CSL BEHRING AUSTRALIA TO BEGIN ONSHORE DEVELOPMENT OF ANTI-SARS-COV-2 PLASMA PRODUCT

* PRODUCT WILL BE DEVELOPED USING DONATIONS OF PLASMA MADE IN AUSTRALIA BY PEOPLE WHO HAVE RECOVERED FROM COVID-19

* EXPECTS UPTO 800 PLASMA DONATIONS NEEDED TO PRODUCE SUFFICIENT COVID-19 IMMUNOGLOBULIN TO TREAT 50-100 SERIOUSLY ILL PEOPLE UNDER CLINICAL TRIAL

* PRODUCT TO TREAT PEOPLE WITH SERIOUS COMPLICATIONS OF COVID-19, PARTICULARLY THOSE WHOSE ILLNESS IS PROGRESSING TOWARDS NEED FOR VENTILATION Source: bit.ly/35ydfPM Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below